<table stylecode="Noautorules" width="650" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tfoot>
<tr>
<td colspan="2">Should be administered at least 4 hours prior to WELCHOL
                                        <sup>a</sup>
</td>
</tr>
<tr>
<td colspan="2">No significant alteration of warfarin drug levels with warfarin and WELCHOL coadministration in an study which did not evaluate warfarin pharmacodynamics (INR).
                                        <sup>b</sup>
<content stylecode="italics">in vivo</content>
<content stylecode="italics">[See Post-marketing Experience ( )]
                                            <linkhtml href="#s062">6.2</linkhtml>
</content>
</td>
</tr>
<tr>
<td colspan="2">Cyclosporine levels should be monitored and, based on theoretical grounds, cyclosporine should be administered at least 4 hours prior to WELCHOL.
                                        <content stylecode="italics">
<sup>c</sup>
</content>
</td>
</tr>
<tr>
<td colspan="2">Patients receiving concomitant metformin ER and colesevelam should be monitored for clinical response as is usual for the use of anti-diabetes drugs.
                                        <sup>d</sup>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="center" colspan="2">
<content stylecode="bold">Table 4 Drugs Tested in Binding or Drug Interaction Testing or With Post-Marketing Reports
                                            <content stylecode="italics">In Vitro</content>
<content stylecode="italics">In Vivo</content>
</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drugs with a known interaction with colesevelam: Decrease in exposure of coadministered drug
                                        <br/>
</td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">cyclosporine , glimepiride , glipizide , glyburide , levothyroxine , olmesartan medoxomil , and oral contraceptives containing ethinyl estradiol and norethindrone
                                        <sup>c</sup>
<sup>a</sup>
<sup>a</sup>
<sup>a</sup>
<br/>
<sup>a</sup>
<sup>a</sup>
<br/>
<br/>
<sup>a</sup>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drugs with a known interaction with colesevelam: Increase in exposure of coadministered drug
                                        <br/>
</td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">metformin extended release (ER)
                                        <sup>d</sup>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drug(s) with postmarketing reports consistent with potential drug-drug interactions when coadministered with WELCHOL
                                        <br/>
<br/>
</td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">phenytoin , warfarin
                                        <sup>a</sup>
<sup>b</sup>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">Drugs that do not interact with colesevelam based on or testing
                                        <br/>
<content stylecode="italics">in vitro</content>
<content stylecode="italics">in vivo</content>
</td>
<td stylecode="Toprule Botrule Lrule Rrule" valign="top">aspirin, atenolol, cephalexin, ciprofloxacin, digoxin, enalapril, fenofibrate, lovastatin, metformin, metoprolol, phenytoin , pioglitazone, rosiglitazone, quinidine, repaglinide, sitagliptin, valproic acid, verapamil, warfarin
                                        <br/>
<br/>
<sup>a</sup>
<br/>
<br/>
<sup>b</sup>
</td>
</tr>
</tbody>
</table>